SFN and thyroid cancer, nonmedullary, 2: The increased expression observed for the SFN gene in the malignant tumor samples group (PTC and FTC) (group 2) and in the PTC group (group 4) compared to the group of normal and benign samples (group 1), and its reduced expression in the FTC group (group 5) when compared to the PTC samples, in both the PCR Array and RT-qPCR analyses, indicated this gene as a promising diagnostic marker for PTC.